Agilent unveils much anticipated end-to-end digital pathology workflow solution
Agilent unveils much anticipated end-to-end digital pathology workflow solution
Agilent Technologies has introduced a highly anticipated end-to-end solution for digital pathology that brings together best-in-class products from Agilent, Visiopharm, Proscia, and Hamamatsu Photonics.
Agilent and Visiopharm have collaborated since 2020, developing an integrated solution comprising Visiopharm’s portfolio of leading artificial intelligence (AI)-driven precision pathology software and Agilent’s automated pathology staining solutions. The collaboration also includes a distribution agreement, initially in Europe but now expanded to include the US and Canada. Agilent and Visiopharm have also broadened their development services to include digital pathology applications that will increasingly benefit the global pharmaceutical industry by providing access to Visiopharm’s AI capabilities to deliver innovative, high-quality companion diagnostics.
“Agilent has meticulously and diligently been working toward the development of a complete end-to-end digital pathology solution to help pathology labs increase efficiency, clinical utility, quality control, and ultimately patient care,” said Lou Welebob, vice president and general manager of Agilent’s Pathology Division, Diagnostics and Genomics Group.
“Our objective was to work with industry innovators, starting with Visiopharm as our initial partner. We are now excited to an-
nounce that we have expanded our offering through the addition of two other partners Proscia and Hamamatsu, in this fast-growing digital pathology space,” Welebob added.
Proscia is a leader in digital pathology solutions, and Hamamatsu, a leading provider of whole slide imaging systems.
For more information, visit: www.agilent.com
Digital issue: Please click here for more information
